Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brecanavir with Ritonavir and NRTIs in HIV-1
NCT00257621Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2004
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brecanavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Primary endpoints: Percentage of subjects with plasma HIV-1 RNA <400 copies/ml, Incidence of serious adverse events, rash and thyroid function abnormalities and 1 more. Started Oct 2004; status: completed.
02
Drugs
brecanavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00257621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257621.